Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 713-719    DOI: 10.31083/j.ejgo.2020.05.5129
Original Research Previous articles | Next articles
Effect of CD59-targeted multi-directional intervention on transmembrane apoptotic signal transduction of cervical cancer HeLa cells
Tao Wei1, 2, , Mei-Hua Gao1, †, *(), Ying Li3
1Department of Immunology, Medical College of Qingdao University, Qingdao 266071, P. R. China
2Department of Medical Affairs, Hospital office, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, 266000, P. R. China
3Department of Blood Transfusion, The affiliated hospital of Qingdao university, Qingdao 266000, P. R. China
Download:  PDF(2550KB)  ( 88 ) Full text   ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: With GPI-anchored protein CD59 as the target, the effect of the abnormal expression of the CD59 gene on the proliferation and apoptosis of cervical cancer HeLa cells was studied to investigate the mechanism of the malignant proliferation of cervical cancer cells. Materials and Methods: Recombinant plasmid pSUPER-siCD59 (CD59 RNA interference) was transfected into HeLa cells via liposome transfection. The plasmid expressed green fluorescent proteins that enabled the observation of the transfection efficiency and was separately transfected. The co-transfection of a pIRES-WTCD59 (wild-type CD59) plasmid, pIRES-MCD59 (with CD59W40 active site mutation) plasmid, and pLeGFP plasmid helped the direct observation of the transfection efficiency, which was examined via an inverted fluorescence microscope at 24, 48, and 72 hours after transfection. Then, the stable transfected cell lines were screened by G418. Western blot, RT-PCR, and immunofluorescence were used to detect the gene and protein expression of CD59 in the stably transfected HeLa cell lines, and the differences were evaluated. The short peptide seal specific to CD59 was exerted on the HeLa cells. Cell proliferation was detected by MTT colorimetric assay, and apoptosis was detected by TUNEL and flow cytometry. Results: The proliferation activity of the HeLa cells with CD59RNAi, CD59W40 active site mutations, and the short peptide seal specific to CD59 significantly decreased. In particular, the proliferation activity of the HeLa cells treated with a high dose of the short peptide seal specific to CD59 was significantly reduced, while the proliferation activity of the HeLa cells with a high expression of CD59 was significantly enhanced. Conclusion: As an inhibitory regulatory protein in the terminal stage of complement regulation, CD59 can promote the proliferation of cervical cancer HeLa cells via inhibiting the dissolution effect of the complement on the cells, promoting transmembrane activation signal transduction, and inhibiting apoptotic signal transduction. Thus, this study provides a new avenue for the clinical treatment of cervical cancer.
Key words:  CD59 knockout      Short-peptide seal      RNAi      Hela cell      Proliferation      Apoptosis     
Submitted:  02 July 2019      Accepted:  18 September 2019      Published:  15 October 2020     
*Corresponding Author(s):  MEI-HUA GAO     E-mail:  gaomh14632@163.com
About author:  Contributed equally.

Cite this article: 

Tao Wei, Mei-Hua Gao, Ying Li. Effect of CD59-targeted multi-directional intervention on transmembrane apoptotic signal transduction of cervical cancer HeLa cells. European Journal of Gynaecological Oncology, 2020, 41(5): 713-719.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5129     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/713

[1] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[2] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[3] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[4] F. Oyama, Y. Asano, H. Shimoda, K. Horie, J. Watanabe, Y. Yokoayama. Morphological analysis of peritoneal dissemination of ovarian cancer based on levels of carbonyl reductase 1 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 352-360.
[5] J. Zheng, P. Liu, C. Li, L. Cheng, Y. Xu, F. Guo, M. Xiong, T. Song, Y. Li, F. Yan, H. Xu, B. Chen, J. Zhang. Umbilical cord-derived mesenchymal stem cells efficiently induced apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 839-845.
[6] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634-639.
[7] Yanhua Li, Rui Liu, Jiang Li, Xudong Dong, Jinsong Shen, Shaoyuan Wu. Isoflurane promotes proliferation and invasion of cervical carcinoma cells via downregulation of miR-375 expression[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 368-372.
[8] T. Hanikezi, W. Shaadaiti, A. Mayinuer, J.D. Zhao, M. Guzainuer, A. Mourboul, A. Zufeiya. Impacts of isoliquiritigenin on proliferation and apoptosis of human cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 425-430.
[9] G. Yu, J. Liu, X. Sui, T. Wang, W. Wang, G. Qu. Upregulation of ATF3 expression inhibit the proliferation of human uterine serous carcinoma in vitro[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 984-987.
[10] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[11] M. Terzic, I. Likic Ladjevic, N. Ladjevic, S. Terzic, J. Dotlic, N. Arsenovic, A. S. Laganà, A. Vereczkey. The longest period to recurrence of granulosa cell ovarian tumor: 41 years after initial diagnosise[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 800-802.
[12] Haiyu Tang, Tianyang Gao, Xin Ren, Jin Wu, Jinqian Zhang, Zhi Zhang, Yan Yan. The effect of RNAi silencing Tspan5 expression on the proliferation and migration of human choriocarcinoma cell line JEG-3[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 595-599.
[13] Ling Wang, Xiao-tong Wu, Bo-wei Wang, Qiang Wang, Li-ying Han. miR-145 regulates proliferation and chemotherapy sensitivity of ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 634-640.
[14] J.P. Zhang, L.L. Feng, H.F. Zhan, Y. Liu, X.C. Wang. Stromal cell-derived factor 1 alpha induce epithelial mesenchymal transition of Hela cells[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 933-937.
[15] R. Brightwell, K. Eng, S. Lele. Use of hematologic biomarkers during chemotherapy predicts survival in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 378-381.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[7] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[8] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[9] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .
[10] E. Yilmaz, E. I. Coskun, C. Koc, N. Sahin, B. Isik, B. Ciplak. Isolated recurrence of early-stage cervical cancer in the abdominal wall with suboptimal surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 485 -487 .